On Thursday, Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.
Amphastar is a biopharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products.
The company reported sales of $186.5 million, up 20% year over year, missing the consensus of $188.81 million.
Jack Zhang, Amphastar’s President and Chief Executive Officer, commented, “We are incredibly proud that in 2024, we exceeded our long-term goal of achieving $100 million in annual sales for Primatene MIST, and we look forward to continuing to grow the brand. Furthermore, BAQSIMI showed strong factory sales growth of 12% compared to the fourth quarter of last year. As we look ahead to 2025, we plan to continue developing and growing our proprietary pipeline.”
Also Read: JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Primatene MIST exceeded the long-term goal of $100 million in annual sales (around $29 million in the quarter), while BAQSIMI contributed $41.8 million in direct sales during the fourth quarter alone ($126.9 million for the full year).
JP Morgan says the company has seen some setbacks over the past several months, including a competitive approval for glucagon (~15% of Amphastar revenues) and several pipeline delays.
Analyst Ekaterina Knyazkova sees limited downside for the stock as Amphastar shares are now in the low $30s. Primatene MIST and Baqsimi continue growing, with the current valuation reflecting little value for Amphastar’s extensive R&D efforts and pipeline.
JP Morgan maintains the Overweight rating for Amphastar’s stock with a price target of $45.
Price Action: AMPH stock is down 8.35% at $28.86 at the last check Friday.
Read Next:
Photo by Ground Picture on Shutterstock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.